Friday, September 23, 2011

Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress

THOUSAND OAKS, Calif., Sept. 23, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

Read the rest of this entry

Posted in Press Releases

Monday, September 19, 2011

FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy

Prolia is the First-and-Only Medicine Approved for Cancer Treatment-Induced Bone Loss

THOUSAND OAKS, Calif., Sept. 19, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer. In patients with prostate cancer, Prolia also reduced the incidence of vertebral fractures.  Prolia is the first-and-only therapy approved by the FDA for cancer treatment-induced bone loss in patients undergoing hormone ablation therapy.

Read the rest of this entry

Posted in Press Releases

Saturday, September 17, 2011

Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover. The data were presented at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego.

Read the rest of this entry

Posted in Press Releases

Thursday, September 15, 2011

Amgen to Present at the UBS Global Life Sciences Conference

THOUSAND OAKS, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, Sept. 20, 2011, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Thursday, September 15, 2011

Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits

THOUSAND OAKS, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/—Each year, thousands of Amgen staff generously devote their personal time, energy and talents to a variety of charitable organizations. To recognize these exceptional efforts, the Amgen Foundation today announced the 11 recipients of the 2011 Amgen Excellence in Volunteering Awards.

Read the rest of this entry

Posted in Press Releases